Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
06/13/18Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
-Tisotumab Vedotin to be Evaluated as a Monotherapy in Patients Who Have Relapsed or Progressed After Standard of Care Treatment- -Tisotumab Vedotin Represents Fourth Late-Stage Development Program Added to List of Ongoing Pivotal Trials Along with Enfortumab Vedotin and Tucatinib- BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 13, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 inno... 
Printer Friendly Version
06/06/18Seattle Genetics to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Jun. 6, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section. About Seattle Genetics Seattle Gen... 
Printer Friendly Version
06/04/18Seattle Genetics Highlights Additional Analyses from Phase 3 ECHELON-1 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at 2018 ASCO Annual Meeting
Data Continue to Support Superior Clinical Activity of ADCETRIS in Combination with Chemotherapy when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma Results from Patients Treated in North America Demonstrate Two-Year Modified Progression-Free Survival of 84.3 Percent in the ADCETRIS Combination Arm Compared to 73.7 Percent in the ABVD Arm Positive ECHELON-1 Results Supported FDA Approval of ADCETRIS in Combination with Che... 
Printer Friendly Version
06/03/18Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
-Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study- BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Jun. 3, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of updated phase 1 data of enfortumab vedotin, an investigational antibody-drug c... 
Printer Friendly Version
05/17/18Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer
BOTHELL, Wash.--(BUSINESS WIRE)--May 17, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Roger D. Dansey, M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development, most recently from Merck Inc. where he was Therapeutic Area Head for Late Stage Oncology, responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types. “Roger’s... 
Printer Friendly Version
05/17/18Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--May 17, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts from its robust clinical development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, from June 1-5, 2018. “The abstracts being presented at ASCO 2018 highlight the depth of our clinical program in multiple solid tumors and hematologica... 
Printer Friendly Version
05/02/18Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
BOTHELL, Wash.--(BUSINESS WIRE)--May 2, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.m. Pacific Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section. About Seattle Genetics Seattle Gene... 
Printer Friendly Version
04/26/18Seattle Genetics Reports First Quarter 2018 Financial Results
-Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $95.4 Million in the First Quarter- -ADCETRIS Approved by FDA in Frontline Stage III/IV Classical Hodgkin Lymphoma- -ECHELON-2 Data Expected in 2018- -Conference Call Today at 4:30 p.m. ET- BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 26, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the first quarter ended... 
Printer Friendly Version
04/12/18Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 12, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data highlights from nine presentations showcasing the company’s innovative, proprietary antibody-drug conjugate (ADC) platform technologies as well as its emerging immuno-oncology pipeline. Data include preclinical and clinical advances with ADCETRIS® (brentuximab vedotin), ladiratuzumab vedotin, SGN-CD48A and SGN-2FF. Additionally, Seattle Gene... 
Printer Friendly Version
04/05/18Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter Financial Results on April 26, 2018
BOTHELL, Wash.--(BUSINESS WIRE)--Apr. 5, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 26, 2018 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE acces... 
Printer Friendly Version
03/26/18Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash. & TOKYO--(BUSINESS WIRE)--Mar. 26, 2018-- Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated ... 
Printer Friendly Version
03/20/18Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
First FDA-Approved Regimen in Frontline Stage III or IV Classical Hodgkin Lymphoma in More Than 40 Years FDA Approval Based on Clinical Trial Results from the Phase 3 ECHELON-1 Clinical Trial Label Expansion Represents Fifth Indication for ADCETRIS in the U.S.; ECHELON-1 Trial Also Converts Prior Accelerated Approval to Regular Approval in Treatment of Relapsed Systemic Anaplastic Large Cell Lymphoma BOTHELL, Wash.--(BUSINESS W... 
Printer Friendly Version
03/15/18Seattle Genetics Appoints Dr. Alpna Seth to Board of Directors
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 15, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Alpna Seth, Ph.D. has been appointed to the company’s Board of Directors. Dr. Seth has more than 20 years of global experience in the healthcare and biotechnology/pharmaceutical industry, including senior leadership positions at Biogen. She currently serves as Chief Operating Officer of Vir Biotechnology, a San Francisco-based biotechnology company... 
Printer Friendly Version
03/13/18Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 13, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section. About Seattle Genetics Seattle Genetics is ... 
Printer Friendly Version
03/09/18Seattle Genetics Completes Acquisition of Cascadian Therapeutics
-Transaction Provides Global Rights to Tucatinib, a Potentially Best-in-Class Tyrosine Kinase Inhibitor for HER2-Positive Metastatic Breast Cancer- -Ongoing Pivotal Trial HER2CLIMB Expected to Complete Enrollment in 2019- BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 9, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced it has completed its previously announced acquisition of Cascadian Therapeutics, Inc. The most advanced progr... 
Printer Friendly Version
03/09/18Seattle Genetics Completes Tender Offer for All Shares of Cascadian Therapeutics
BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 9, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the expiration of the tender offer (the “Offer”) by a wholly owned subsidiary, “Merger Sub”, for all of the shares of common stock of Cascadian Therapeutics, Inc. (Nasdaq:CASC), for a price of $10.00 per share in cash, without interest, less any applicable withholding taxes. The Offer expired at 12:00 midnight, New York City time, on March 9, 2018. Seattl... 
Printer Friendly Version
03/07/18Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma
Antibody-Drug Conjugate (ADC) SGN-CD48A Being Evaluated as Monotherapy, With Innovative Linker Technology That Highlights Continued Industry Leadership in ADCs BOTHELL, Wash.--(BUSINESS WIRE)--Mar. 7, 2018-- Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in a phase 1 clinical trial evaluating the safety and tolerability of SGN-CD48A for patients with relapsed or refractory multiple myeloma (MM). SGN-CD... 
Printer Friendly Version
02/27/18Seattle Genetics to Present at Cowen and Company 38th Annual Health Care Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 27, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018 at 9:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section. About Seattle Genetics Seattle Genet... 
Printer Friendly Version
02/16/18Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 16, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) with respect to Seattle Genetics’ proposed acquisition of Cascadian Therapeutics, Inc. (NASDAQ:CASC) expired at 11:59 p.m. on February 15, 2018. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the tend... 
Printer Friendly Version
02/09/18Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
-Companies to Evaluate Novel Bispecific Immuno-Oncology Agents that Combine Pieris’ Anticalin Technology with Select Seattle Genetics Cancer-Targeted Antibodies- BOSTON & BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 9, 2018-- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seatt... 
Printer Friendly Version
02/08/18Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc.
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 8, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc. (NASDAQ:CASC) at a price of $10.00 per share net to the seller in cash, without interest, less any applicable withholding taxes (the “Offer”). The Offer is being made... 
Printer Friendly Version
02/06/18Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results
-Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $307.6 Million in 2017, Including $83.7 Million in the Fourth Quarter- -ECHELON-1 Supplemental BLA for ADCETRIS in Combination with Chemotherapy for Frontline Advanced Classical Hodgkin Lymphoma Granted FDA Priority Review and PDUFA Action Date of May 1, 2018- -ECHELON-2 Data Expected in 2018- -Proposed Acquisition of Cascadian Therapeutics Would Add Th... 
Printer Friendly Version
02/02/18Seattle Genetics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 2, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,730,769 shares of Seattle Genetics’ common stock. Including this option exercise, total gross proceeds to Seattle Genetics from the offering of an aggregate of 13,269,230 shares at a price to the public of $52.00 ... 
Printer Friendly Version
02/01/18Seattle Genetics Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 1, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 11,538,461 shares of its common stock at a price to the public of $52.00 per share. All of the shares are being sold by Seattle Genetics. The gross proceeds to Seattle Genetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approxim... 
Printer Friendly Version
01/31/18Seattle Genetics Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 31, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of $550.0 million of shares of its common stock. All of the shares are being offered by Seattle Genetics. In addition, Seattle Genetics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $82.5 million of shares of its common stock solely to cover ... 
Printer Friendly Version
01/31/18Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline
-Enhances Seattle Genetics’ Portfolio of Solid Tumor Programs with Potential Rapid Registrational Pathways- -Provides Global Rights to Pivotal Phase 2 Program in Development for HER2-Positive Metastatic Breast Cancer- -Conference Call Today at 8:30 a.m. ET- BOTHELL, Wash. & SEATTLE--(BUSINESS WIRE)--Jan. 31, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc. (Nasdaq:CASC) today announced the... 
Printer Friendly Version
01/22/18Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy
Approval Based on Positive Phase 3 ALCANZA Trial Results, which Demonstrated a Highly Statistically Significant Improvement in Rate of Objective Response Lasting at Least Four Months, Median Progression-Free Survival, and Improvement in Symptom Burden in ADCETRIS Arm BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 22, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) reported today that its collaborator, Takeda Pharmaceutical Company Limited, announced that ... 
Printer Friendly Version
01/18/18Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 18, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2017 financial results on Tuesday, February 6, 2018 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/08/18Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference
-Continued Progress In Establishing ADCETRIS® (brentuximab vedotin) as the Foundation of Care for CD30-Expressing Lymphomas- -Two Solid Tumor ADC Programs Advancing Under Accelerated Approval Pathways- -Multiple Collaborator ADC Programs in Late-Stage Trials for Range of Tumor Types- BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 8, 2018-- Seattle Genetics, Inc. (NASDAQ: SGEN) highlighted today the progress of its pipeline... 
Printer Friendly Version
01/02/18FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
-PDUFA Action Date May 1, 2018- -Submission Based on Positive Results from the Phase 3 ECHELON-1 Clinical Trial- -FDA Previously Granted Breakthrough Therapy Designation for ADCETRIS in Frontline Advanced Hodgkin Lymphoma- BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 2, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biolo... 
Printer Friendly Version